Longboard Pharmaceuticals, Inc. announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neuroinflammatory conditions. The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose clinical study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LP659 in up to 48 healthy adult volunteers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.4 USD | -2.11% | +0.25% | +238.31% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+238.31% | 810M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- LBPH Stock
- News Longboard Pharmaceuticals, Inc.
- Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers